Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID W CLEAVER

Allopathic & Osteopathic Physicians Dermatology

NPI
1295932648
CMS profile
286245
Location
KIRKSVILLE, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$54,972.52

171 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 171 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID W CLEAVER

NPI 1295932648 · CMS profile ID 286245

Allopathic & Osteopathic Physicians / Dermatology

KIRKSVILLE, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 171 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295932648?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID W CLEAVER, NPI 1295932648, CMS profile ID 286245. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 171 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295932648?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). DAVID W CLEAVER, NPI 1295932648, CMS profile ID 286245. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 171 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295932648?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
DAVID W CLEAVER, NPI 1295932648, CMS profile ID 286245, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 171 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1295932648?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

171 matching records · $54,972.52 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 171 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 171.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $26.2308/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103479217 CMS
ABBVIE INC. $116.2308/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103479219 CMS
Lilly USA, LLC $15.2108/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136135065 CMS
Arcutis Biotherapeutics, Inc. $13.5008/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121042930 CMS
ABBVIE INC. $2.5508/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103479213 CMS
ABBVIE INC. $18.4908/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103479215 CMS
Incyte Corporation $15.2908/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141312197 CMS
PFIZER INC. $20.3108/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131881751 CMS
ABBVIE INC. $116.1108/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103479211 CMS
ABBVIE INC. $1,274.5808/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104181056 CMS
ABBVIE INC. $22.7008/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103479209 CMS
E.R. Squibb & Sons, L.L.C. $130.7907/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101492961 CMS
ABBVIE INC. $17.7707/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103479207 CMS
Lilly USA, LLC $18.1007/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136158735 CMS
Arcutis Biotherapeutics, Inc. $13.0907/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121042932 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $85.0007/10/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152141049 CMS
Lilly USA, LLC $12.1707/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136137298 CMS
Janssen Biotech, Inc. $23.6206/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078788804 CMS
Organogenesis Inc. $15.9406/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145423246 CMS
E.R. Squibb & Sons, L.L.C. $26.1606/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101492939 CMS
Lilly USA, LLC $17.1106/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136145465 CMS
Arcutis Biotherapeutics, Inc. $11.6106/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121042924 CMS
E.R. Squibb & Sons, L.L.C. $34.8006/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101492946 CMS
Incyte Corporation $24.3006/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141317811 CMS
LEO Pharma Inc. $23.6906/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152624075 CMS
Lilly USA, LLC $13.4306/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136130918 CMS
ABBVIE INC. $23.4705/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103479205 CMS
E.R. Squibb & Sons, L.L.C. $5,610.0005/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101492924 CMS
Lilly USA, LLC $17.8305/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136145467 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $18.6305/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153807601 CMS
Arcutis Biotherapeutics, Inc. $13.9305/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121042926 CMS
E.R. Squibb & Sons, L.L.C. $13.3805/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101492928 CMS
UCB, Inc. $17.6805/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143097177 CMS
ABBVIE INC. $15.8205/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103479203 CMS
E.R. Squibb & Sons, L.L.C. $113.9305/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101492932 CMS
E.R. Squibb & Sons, L.L.C. $2,660.0005/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101492935 CMS
ABBVIE INC. $22.3804/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103479201 CMS
E.R. Squibb & Sons, L.L.C. $23.3404/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101492884 CMS
Amgen Inc. $22.1804/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117225546 CMS
Janssen Biotech, Inc. $99.9904/24/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078788756 CMS
E.R. Squibb & Sons, L.L.C. $4,208.0004/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101492887 CMS
E.R. Squibb & Sons, L.L.C. $92.4604/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101492891 CMS
Lilly USA, LLC $17.3904/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136150643 CMS
Arcutis Biotherapeutics, Inc. $10.6304/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121042928 CMS
Novartis Pharmaceuticals Corporation $39.0004/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086734319 CMS
ABBVIE INC. $1,247.7504/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103145553 CMS
E.R. Squibb & Sons, L.L.C. $72.0004/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101492876 CMS
ABBVIE INC. $1,725.0004/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103145551 CMS
Regeneron Healthcare Solutions, Inc. $48.4404/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114027124 CMS
ABBVIE INC. $39.4404/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103479199 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $66,899.55 141
PY2020 $22,739.12 47
PY2021 $40,497.18 105
PY2022 $46,785.39 157
PY2023 $80,047.39 187
PY2024 $54,972.52 171
PY2025 $59,540.40 186

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $99,008.95 28
PY2024 Principal investigator $125,513.70 22
PY2023 Recipient $1,450.46 7
PY2023 Principal investigator $28,957.94 19
PY2022 Principal investigator $14,726.10 19
PY2021 Principal investigator $30,009.40 19
PY2020 Principal investigator $52,508.06 30
PY2019 Principal investigator $66,551.88 24

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $4,230.00 12/25/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175411840
Principal investigator 1 Janssen Research & Development, LLC $1,345.00 12/15/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175411759
Principal investigator 1 Janssen Research & Development, LLC $120.00 12/12/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175411833
Principal investigator 1 Janssen Research & Development, LLC $1,745.00 12/01/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175411770
Principal investigator 1 ABBVIE INC. $150.00 11/05/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY PC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202522409
Principal investigator 1 Janssen Research & Development, LLC $2,855.00 10/24/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175411826
Principal investigator 1 Janssen Research & Development, LLC $243.17 10/23/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175411794
Principal investigator 1 Janssen Research & Development, LLC $18,160.28 10/10/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175411765
Principal investigator 1 Janssen Research & Development, LLC $4,266.00 09/22/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175411782
Principal investigator 1 Janssen Research & Development, LLC $3,490.00 09/08/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175411845
Principal investigator 1 Janssen Research & Development, LLC $2,133.00 09/01/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175411808
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 08/22/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184229987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 08/22/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184229989
Principal investigator 1 ABBVIE INC. $8,133.00 08/06/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY PC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202502851
Principal investigator 1 Janssen Research & Development, LLC $2,511.00 07/28/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175411776
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 07/18/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184217491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 07/18/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184217493
Principal investigator 1 Janssen Research & Development, LLC $4,932.00 06/30/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175411741
Principal investigator 1 Eli Lilly and Company $9,382.00 06/25/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY, P.C.
OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS No dispute reported 06/30/2026 1187883314
Principal investigator 1 Janssen Research & Development, LLC $7,211.00 06/23/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175411802
Principal investigator 1 Janssen Research & Development, LLC $5,474.00 05/26/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175411814
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 05/21/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184197439
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 05/21/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184197441
Principal investigator 1 Janssen Research & Development, LLC $3,242.00 04/28/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175411747
Principal investigator 1 Janssen Research & Development, LLC $4,498.00 03/24/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175411820
Principal investigator 1 Janssen Research & Development, LLC $5,455.00 03/03/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175411753
Principal investigator 1 Janssen Research & Development, LLC $1,624.00 02/21/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175411735
Principal investigator 1 Janssen Research & Development, LLC $5,417.00 01/27/2025 Non-covered Recipient Entity
CLEAVER DERMATOLOGY
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175411788